Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors Ampligen's anti-tumor potential is demonstrated with
Buffalo, N.Y. (PRWEB) May 12, 2021 - Dr. Kalinski has attracted more than $22.5 million in active grants- His innovations have potential to significantly